BrainsWay Enhances Commercial Leadership Team with the Addition of Fran Hackett as Vice President of North American Sales
16 February 2021 - 11:30PM
BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the
“Company”), a global leader in the advanced non-invasive treatment
of brain disorders, today announced the addition of Fran Hackett as
Vice President of North American Sales effective February 16, 2021.
“As a veteran sales leader with a robust
background across varied medical markets, Fran’s addition will be
critical to this phase of the Company’s growth,” said Hadar Levy,
Senior Vice President and General Manager of BrainsWay. “He has
been instrumental in building industry-leading teams, and I am
excited to have him take over our commercial efforts in North
America.”
“BrainsWay has great momentum in establishing
Deep TMS as the leading, non-pharmacological treatment for a range
of debilitating brain disorders, and it is my distinct honor to
have this opportunity to lead the North American sales efforts for
this growing company,” said Mr. Hackett. “I look forward to
leveraging my experience building dynamic teams to help expand both
access and awareness to this novel, lifesaving technology.”
Mr. Hackett brings more than 30 years of
domestic and international sales, business development, and
executive leadership to BrainsWay. Most recently, he served as
Senior Vice President of Global Sales and Marketing for Alter G, a
privately-held rehabilitation and advanced performance company
where he led the restructure and enhancement of the global sales
and distribution network. Prior to Alter G, Mr. Hackett was the CEO
of RTI Group, a radiology safety company focused on quality
assurance solutions for X-ray modalities. Earlier in his career, he
held sales and marketing roles of increasing responsibility in both
private and public medical device companies.
About BrainsWayBrainsWay is a
commercial stage medical device company focused on the development
and sale of non-invasive neurostimulation products using the
Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep
TMS) platform technology. The Company received marketing
authorization from the U.S. Food and Drug Administration (FDA) for
its products for a variety of patient populations, including in
2013 for patients with major depressive disorder (MDD), in 2018 for
patients with obsessive-compulsive disorder (OCD), and in 2020 for
patients with smoking addiction. BrainsWay is currently conducting
clinical trials of Deep TMS in various psychiatric, neurological,
and addiction disorders. To learn more, please visit
www.brainsway.com
Forward Looking StatementsThis
press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such statements may be preceded by the words “intends,” “may,”
“will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. These forward-looking statements and their
implications are based on the current expectations of the
management of the Company only and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
The following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: inadequacy of financial resources to meet future
capital requirements; changes in technology and market
requirements; delays or obstacles in launching and/or successfully
completing planned studies and clinical trials; failure to obtain
approvals by regulatory agencies on the Company’s anticipated
timeframe, or at all; inability to retain or attract key employees
whose knowledge is essential to the development of Deep TMS
products; unforeseen difficulties with Deep TMS products and
processes, and/or inability to develop necessary enhancements;
unexpected costs related to Deep TMS products; failure to obtain
and maintain adequate protection of the Company’s intellectual
property, including intellectual property licensed to the Company;
the potential for product liability; changes in legislation and
applicable rules and regulations; unfavorable market perception and
acceptance of Deep TMS technology; inadequate or delays in
reimbursement from third-party payers, including insurance
companies and Medicare; inability to commercialize Deep TMS,
including internationally, by the Company or through third-party
distributors; product development by competitors; inability to
timely develop and introduce new technologies, products and
applications, and the effect of the global COVID-19 health pandemic
on our business and continued uncertainty and market impact
relating thereto.
Any forward-looking statement in this press
release speaks only as of the date of this press release. The
Company undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws. More detailed information about the
risks and uncertainties affecting the Company is contained under
the heading “Risk Factors” in the Company’s filings with the U.S.
Securities and Exchange Commission.
Contact: BrainsWay: Hadar LevySVP and General
ManagerHadarL@brainsway.com
Media Contact:Will Johnson(201)
465-8019Brainsway@antennagroup.com
Brainsway (NASDAQ:BWAY)
Historical Stock Chart
From Apr 2024 to May 2024
Brainsway (NASDAQ:BWAY)
Historical Stock Chart
From May 2023 to May 2024